Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60

Authors
Category Systematic review
ConferenceMS Australia's Progress in MS Research Conference 2023
Year 2024
This article has no abstract
Epistemonikos ID: 18df1cc775216892a7e9fafbeafca8914a2860c5
First added on: Feb 16, 2026